Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2012

01-04-2012 | Research Article

System review and metaanalysis of the relationships between five metabolic gene polymorphisms and colorectal adenoma risk

Authors: Zhi-Qiang Zhao, Qing-Kai Guan, Fei-Yun Yang, Peng Zhao, Bing Zhou, Zhi-Jun Chen

Published in: Tumor Biology | Issue 2/2012

Login to get access

Abstract

The relationships between some metabolic (including EPHX1, GSTs and NQO1) gene polymorphisms and colorectal adenoma (CRA) risk have been commonly studied, and no conclusions are available up to now. Therefore, we quantitatively studied the relationships by a metaanalysis. The databases of Medline and Embase were retrieved updated to June 15th, 2011. Crude or adjusted odds ratio (crude OR or adjusted OR) and 95% confidence interval (95%CI) were calculated to present the strength of the associations. Overall, nine case–control studies for EPHX1 Tyr113His and His139Arg, five case–control studies for GSTM1, four studies for GSTP1 Ile105Val, two studies for GSTP1 Ala114Val, six studies for GSTT1 and four studies for NQO1 Pro187Ser were included in this metaanalysis. The results of combined analyses indicated that EPHX1 Tyr113His and His139Arg, GSTT1, GSTM1, GSTP1 Ile105Val and Ala114Val were not associated with CRA risk [crude OR (95%CI): 0.98 (0.90–1.07) and P z-test = 0.65 for EPHX1 His carriers vs. Tyr/Tyr; 1.05 (0.97–1.15) and P z-test = 0.21 for EPHX1 Arg carriers vs. His/His; 1.05 (0.92–1.20) and P z-test = 0.47 for GSTT1 Null vs. Present; 1.01 (0.90–1.13) and P z-test = 0.90 for GSTM1 Null vs. Present; 1.04 (0.92–1.17) and P z-test = 0.56 for G carriers vs. AA for GSTP1 Ile105Val; 0.88 (0.70–1.11) and P z-test = 0.28 for T carriers vs. CC for GSTP1 Ala114Val]. In contrast, Ser allele of NQO1 Ser187Pro might be a modest risk factor for CRA development [1.19 (1.06–1.33) and P z-test = 0.003 for Ser carriers vs. Pro/Pro]. To get more precise evidences, adjusted ORs (95%CI) for EPHX1 Tyr113His, His139Arg, GSTP1 Ile105Val and NQO1 Ser187Pro were also calculated based on adjusted ORs (95%CIs) reported in primary studies. The results still indicated that EPHX1 Tyr113His, His139Arg and GSTP1 Ile105Val were not associated with CRA risk except for NQO1 Ser187Pro. When subgroup analyses were performed for population-based case–control studies or studies in HWE for EPHX1 Tyr113His and His139Arg, and NQO1 Ser187Pro polymorphisms, the results were persistent. Although with modest limitations and biases, this metaanalysis suggests that EPHX1 Tyr113His and His139Arg, GSTT1, GSTM1, GSTP1 Ile105Val and Ala114Val polymorphisms may be not risk factors for CRA development, while Ser allele of NQO1 Ser187 Pro may be a modest risk factor for CRA development, and may be used with other genetic markers for screening CRA in the future.
Literature
1.
2.
3.
Nothlings U, Yamamoto JF, Wilkens LR, Murphy SP, Park SY, Henderson BE, et al. Meat and heterocyclic amine intake, smoking, NAT1 and NAT2 polymorphisms, and colorectal cancer risk in the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev. 2009;18:2098–106.PubMedCrossRef
4.
Northwood EL, Elliott F, Forman D, Barrett JH, Wilkie MJ, Carey FA, et al. Polymorphisms in xenobiotic metabolizing enzymes and diet influence colorectal adenoma risk. Pharmacogenet Genomics. 2010;20:315–26.PubMedCrossRef
5.
Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer. 1975;15:617–31.PubMedCrossRef
6.
Randi G, Edefonti V, Ferraroni M, La Vecchia C, Decarli A. Dietary patterns and the risk of colorectal cancer and adenomas. Nutr Rev. 2010;68:389–408.PubMedCrossRef
7.
Onega T, Goodrich M, Dietrich A, Butterly L. The influence of smoking, gender, and family history on colorectal adenomas. J Cancer Epidemiol. 2010;2010:509347.PubMed
8.
Skjelbred CF, Saebo M, Hjartaker A, Grotmol T, Hansteen IL, Tveit KM, et al. Meat, vegetables and genetic polymorphisms and the risk of colorectal carcinomas and adenomas. BMC Cancer. 2007;7:228.PubMedCrossRef
9.
Huang WY, Chatterjee N, Chanock S, Dean M, Yeager M, Schoen RE, et al. Microsomal epoxide hydrolase polymorphisms and risk for advanced colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2005;14:152–7.PubMedCrossRef
10.
Inoue H, Kiyohara C, Marugame T, Shinomiya S, Tsuji E, Handa K, et al. Cigarette smoking, CYP1A1 MspI and GSTM1 genotypes, and colorectal adenomas. Cancer Res. 2000;60:3749–52.PubMed
11.
Roberts-Thomson IC, Butler WJ, Ryan P. Meat, metabolic genotypes and risk for colorectal cancer. Eur J Cancer Prev. 1999;8:207–11.PubMedCrossRef
12.
Mitrou PN, Watson MA, Loktionov AS, Cardwell C, Gunter MJ, Atkin WS, et al. Role of NQO1C609T and EPHX1 gene polymorphisms in the association of smoking and alcohol with sporadic distal colorectal adenomas: results from the UKFSS Study. Carcinogenesis. 2007;28:875–82.PubMedCrossRef
13.
Ulrich CM, Bigler J, Whitton JA, Bostick R, Fosdick L, Potter JD. Epoxide hydrolase Tyr113His polymorphism is associated with elevated risk of colorectal polyps in the presence of smoking and high meat intake. Cancer Epidemiol Biomarkers Prev. 2001;10:875–82.PubMed
14.
Inoue H, Kiyohara C, Shinomiya S, Marugame T, Tsuji E, Handa K, et al. Glutathione S-transferase polymorphisms and risk of colorectal adenomas. Cancer Lett. 2001;163:201–6.PubMedCrossRef
15.
Zhuang W, Wu XT, Zhou Y, Liu L, Liu GJ, Wu TX, et al. Interleukin10–592 promoter polymorphism associated with gastric cancer among Asians: a meta-analysis of epidemiologic studies. Dig Dis Sci. 2010;55:1525–32.PubMedCrossRef
16.
Luchtenborg M, Weijenberg MP, Kampman E, van Muijen GN, Roemen GM, Zeegers MP, et al. Cigarette smoking and colorectal cancer: APC mutations, hMLH1 expression, and GSTM1 and GSTT1 polymorphisms. Am J Epidemiol. 2005;161:806–15.PubMedCrossRef
17.
Barker HJ, Alpert LC, Compton CC, Maslen A, Kirby GM. Loss of glutathione S-transferase (GST) mu phenotype in colorectal adenocarcinomas from patients with a GSTM1 positive genotype. Cancer Lett. 2002;177:65–74.PubMedCrossRef
18.
Tiemersma EW, Kloosterman J, Bunschoten A, Kok FJ, Kampman E. Role of EPHX genotype in the associations of smoking and diet with colorectal adenomas. IARC Sci Publ. 2002;156:491–3.PubMed
19.
Lin HJ, Probst-Hensch NM, Louie AD, Kau IH, Witte JS, Ingles SA, et al. Glutathione transferase null genotype, broccoli, and lower prevalence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 1998;7:647–52.PubMed
20.
Lin HJ, Zhou H, Dai A, Huang HF, Lin JH, Frankl HD, et al. Glutathione transferase GSTT1, broccoli, and prevalence of colorectal adenomas. Pharmacogenetics. 2002;12:175–9.PubMedCrossRef
21.
Lin HJ, Probst-Hensch NM, Ingles SA, Han CY, Lin BK, Lee DB, et al. Glutathione transferase (GSTM1) null genotype, smoking, and prevalence of colorectal adenomas. Cancer Res. 1995;55:1224–6.PubMed
22.
Tiemersma EW, Bunschoten A, Kok FJ, Glatt H, de Boer SY, Kampman E. Effect of SULT1A1 and NAT2 genetic polymorphism on the association between cigarette smoking and colorectal adenomas. Int J Cancer. 2004;108:97–103.PubMedCrossRef
23.
Tijhuis MJ, Visker MH, Aarts JM, Laan W, de Boer SY, Kok FJ, et al. NQO1 and NFE2L2 polymorphisms, fruit and vegetable intake and smoking and the risk of colorectal adenomas in an endoscopy-based population. Int J Cancer. 2008;122:1842–8.PubMedCrossRef
24.
Tijhuis MJ, Wark PA, Aarts JM, Visker MH, Nagengast FM, Kok FJ, et al. GSTP1 and GSTA1 polymorphisms interact with cruciferous vegetable intake in colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev. 2005;14:2943–51.PubMedCrossRef
25.
Moore LE, Huang WY, Chatterjee N, Gunter M, Chanock S, Yeager M, et al. GSTM1, GSTT1, and GSTP1 polymorphisms and risk of advanced colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2005;14:1823–7.PubMedCrossRef
26.
Hou L, Chatterjee N, Huang WY, Baccarelli A, Yadavalli S, Yeager M, et al. CYP1A1 Val462 and NQO1 Ser187 polymorphisms, cigarette use, and risk for colorectal adenoma. Carcinogenesis. 2005;26:1122–8.PubMedCrossRef
27.
Tranah GJ, Giovannucci E, Ma J, Fuchs C, Hankinson SE, Hunter DJ. Epoxide hydrolase polymorphisms, cigarette smoking and risk of colorectal adenoma in the Nurses' Health Study and the Health Professionals Follow-up Study. Carcinogenesis. 2004;25:1211–8.PubMedCrossRef
28.
Cortessis V, Siegmund K, Chen Q, Zhou N, Diep A, Frankl H, et al. A case–control study of microsomal epoxide hydrolase, smoking, meat consumption, glutathione S-transferase M3, and risk of colorectal adenomas. Cancer Res. 2001;61:2381–5.PubMed
29.
Liu L, Zeng F, Wang K, Huang J, Xin L, Zhu PQ. Meta-analysis of the association between VEGF-634 G > C and risk of malignancy based on 23 case–control studies. J Cancer Res Clin Oncol. 2011;137:1027–36.PubMedCrossRef
30.
Attia J, Thakkinstian A, D'Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol. 2003;56:297–303.PubMedCrossRef
31.
Liu L, Zhuang W, Wang RQ, Mukherjee R, Xiao SM, Chen Z, et al. Is dietary fat associated with the risk of colorectal cancer? A meta-analysis of 13 prospective cohort studies. Eur J Nutr. 2011;50:173–84.PubMedCrossRef
32.
33.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
34.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRef
35.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef
36.
Omiecinski CJ, Hassett C, Hosagrahara V. Epoxide hydrolase—polymorphism and role in toxicology. Toxicol Lett. 2000;112–113:365–70.PubMedCrossRef
37.
Li X, Hu Z, Qu X, Zhu J, Li L, Ring BZ, et al. Putative EPHX1 enzyme activity is related with risk of lung and upper aerodigestive tract cancers: a comprehensive meta-analysis. PLoS One. 2011;6:e14749.PubMedCrossRef
38.
Sims P, Grover PL, Swaisland A, Pal K, Hewer A. Metabolic activation of benzo(a)pyrene proceeds by a diol-epoxide. Nature. 1974;252:326–8.PubMedCrossRef
39.
Brown B, Avalos J, Lee C, Doolittle D. The effect of tobacco smoke, nicotine, and cotinine on the mutagenicity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL). Mutat Res. 2001;494:21–9.PubMed
40.
Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet. 1994;3:421–8.PubMedCrossRef
41.
Hosagrahara VP, Rettie AE, Hassett C, Omiecinski CJ. Functional analysis of human microsomal epoxide hydrolase genetic variants. Chem Biol Interact. 2004;150:149–59.PubMedCrossRef
42.
Hassett C, Lin J, Carty CL, Laurenzana EM, Omiecinski CJ. Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression. Arch Biochem Biophys. 1997;337:275–83.PubMedCrossRef
43.
Yang X, Liang SH, Weyant DM, Lazarus P, Gallagher CJ, Omiecinski CJ. The expression of human microsomal epoxide hydrolase is predominantly driven by a genetically polymorphic far upstream promoter. J Pharmacol Exp Ther. 2009;330:23–30.PubMedCrossRef
44.
Kiyohara C, Otsu A, Shirakawa T, Fukuda S, Hopkin JM. Genetic polymorphisms and lung cancer susceptibility: a review. Lung Cancer. 2002;37:241–56.PubMedCrossRef
45.
Lampe JW. Interindividual differences in response to plant-based diets: implications for cancer risk. Am J Clin Nutr. 2009;89:1553S–7.PubMedCrossRef
46.
Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact. 2000;129:77–97.PubMedCrossRef
47.
Joseph P, Jaiswal AK. NAD(P)H:quinone oxidoreductase1 (DT diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc Natl Acad Sci USA. 1994;91:8413–7.PubMedCrossRef
48.
Kuehl BL, Paterson JW, Peacock JW, Paterson MC, Rauth AM. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer. 1995;72:555–61.PubMedCrossRef
49.
Xue H, Ni P, Lin B, Xu H, Huang G. X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and gastric cancer risk: a HuGE review and meta-analysis. Am J Epidemiol. 2011;173:363–75.PubMedCrossRef
Metadata
Title
System review and metaanalysis of the relationships between five metabolic gene polymorphisms and colorectal adenoma risk
Authors
Zhi-Qiang Zhao
Qing-Kai Guan
Fei-Yun Yang
Peng Zhao
Bing Zhou
Zhi-Jun Chen
Publication date
01-04-2012
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0287-x

Other articles of this Issue 2/2012

Tumor Biology 2/2012 Go to the issue

Review

Targeting the endothelin axis in prostate carcinoma

Research Article

Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma

Research Article

DNA methylation biomarkers for lung cancer

Research Article

Promoter methylation status and expression of estrogen receptor alpha in familial breast cancer patients

Research Article

Diagnostic and prognostic utility of methylation and protein expression patterns of myopodin in colon cancer

Research Article

Distribution of mast cells in benign odontogenic tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits